Dr. Dinelia Rivera-Burgos
Battelle is pleased to welcome Dr. Dinelia Rivera-Burgos to the Life Sciences Research Team. Dinelia will be applying her analytical and bioanalytical expertise to develop, optimize and quantify new methods and assays for highly toxic substances.
Dinelia joined the Battelle team in February 2016 as a Principal Research Scientist. She brings extensive analytical expertise with particular specialization in chromatography, mass spectrometry, proteomics and metabolomics. In her previous research, she worked on projects for DARPA and other organizations designed to improve the sensitivity of analytical methods and expand the range of matrices that could be used for analysis. In her role at Battelle, she will be primarily focused on development and validation of new assays for chemical agents and other highly toxic substances. Much of her work will support Battelle’s ongoing projects for the Department of Defense (DoD), in particular development of new therapies and vaccines to protect soldiers from chemical and biological weapons.
Prior to coming to Battelle, Dinelia was an NIH Postdoctoral Fellow at the Massachusetts Institute of Technology, where she led drug clearance, pharmacokinetics and IVIVC studies of steroidal and non-steroidal anti-inflammatory drugs. She also directed phase I and phase II drug metabolism studies in 3D humanized liver and lung microphysiological systems. She completed her Ph.D. in Analytical Chemistry at Purdue University, where she designed and optimized trypsin proteolysis methods to enhance protein sequence coverage in proteomic analyses. She earned her B.S. in Chemistry from the University of Puerto Rico. Her work on drug development using human multi-organ microfluidic devices earned her the American Chemical Society Young Investigator Award in Chemical Toxicology in 2013 and 2015.
She is currently providing Analytical Chemistry support for a DoD project to develop new therapies against nerve agents, including validation of LC-MS/MS methods that will be used to quantify organo-phosporus compounds in plasma-derived samples. Her work will be used to determine the toxicokinetic profile for each agent and establish the correct therapeutic dose of potential therapies.
In the future, she hopes to focus on growing Battelle’s capabilities in large molecule analytics. New methods are needed to improve the sensitivity and throughput of large molecule assays to support development of new therapeutics and diagnostics.